SLC25A35 and metabolic dysfunction-associated steatotic liver disease: By targeting these “lipogenic mitochondria,” through SLC25A35, it is possible to selectively suppress fatty acid esterification in individuals with MASLD while preserving substrate oxidation in the TCA cycle.